Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis

  • Huaidong Wang Key Laboratory of Zoonosis, Ministry of Education, College of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, China
  • Xiaotian Zhang Key Laboratory of Zoonosis, Ministry of Education, College of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, China
  • Yuanxiang Bai Key Laboratory of Zoonosis, Ministry of Education, College of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, China
  • Zipeng Duan Key Laboratory of Zoonosis, Ministry of Education, College of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, China
  • Yan Lin Key Laboratory of Zoonosis, Ministry of Education, College of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, China
  • Guoqing Wang Key Laboratory of Zoonosis, Ministry of Education, College of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, China
  • Fan Li Key Laboratory of Zoonosis, Ministry of Education, College of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, China

Abstract

Multidrug resistant tuberculosis (MDR-TB) is a serious form of tuberculosis (TB). There is no recognized effective treatment for MDR-TB, although there are a number of publications that have reported positive results for MDR-TB. We performed a network meta-analysis to assess the efficacy and acceptability of potential antitubercular drugs. We conducted a network meta-analysis of randomized controlled clinical trials to compare the efficacy and acceptability of five antitubercular drugs, bedaquiline, delamanid, levofloxacin, metronidazole and moxifloxacin in the treatment of MDR-TB. We included eleven suitable trials from nine journal articles and six clinical trials from ClinicalTrials.gov, with data for 1472 participants. Bedaquiline (odds ratio [OR] 2.69, 95% CI 1.02-7.43), delamanid (OR 2.45, 95% CI 1.36-4.89) and moxifloxacin (OR 2.47, 95% CI 1.01, 7.31) were significantly more effective than placebo. For efficacy, the results indicated no statistical significance between each antitubercular drug. For acceptability, the results indicated no statistically significant difference between each compared intervention. There is insufficient evidence to suggest that any one of the five antitubercular drugs (bedaquiline, delamanid, levofloxacin, metronidazole and moxifloxacin) has superior efficacy compared to the others.

Published
2015-04-28
How to Cite
WANG, Huaidong et al. Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis. Journal of Clinical Bioinformatics, [S.l.], v. 5, n. 1, apr. 2015. ISSN 2043-9113. Available at: <http://jclinbioinformatics.com/article/view/60>. Date accessed: 16 aug. 2017. doi: https://doi.org/10.1186/s13336-015-0020-x.